Targeting EGFR signaling may partially rescue the response to chemotherapy in B7-H3-overexpressing COAD patients, providing potential therapeutic strategies for dual targeting of B7-H3 and EGFR to increase the clinical benefit in COAD patients. This evidence concerns the gene EGFR and colon adenocarcinoma.